Clinical Trials

MainTitle

Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

This study has been available
Sponsor
Janssen Sciences Ireland UC

Collaborator
ViiV Healthcare

Information provided by (Responsible Party)
Janssen Sciences Ireland UC
ClinicalTrials.gov Identifier
NCT03847376

First received: February 18, 2019
Last updated: January 6, 2020
Last Verified: January 2020
History of Changes
Purpose

Purpose

The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus (HIV)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the Phase III clinical studies or do not qualify). RPV LA can only be provided if participants are also eligible for cabotegravir Long Acting injections.

Condition Intervention
HIV

Drug : Rilpivirine Long Acting (RPV LA)

Study Type: Expanded Access   What is Expanded Access?
Official Title: Rilpivirine Long Acting Single Patient Requests

Further study details as provided by Janssen Sciences Ireland UC:

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03847376

Contacts

Contact:   Study Contact 1-800-JANSSEN (1-800-526-7736) Janssenmedinfo@its.jnj.com

Sponsors and Collaborators

Janssen Sciences Ireland UC
ViiV Healthcare

Investigators

Study Director: Janssen Sciences Ireland UC Clinical Trial Janssen Sciences Ireland UC
More Information

More Information


Responsible Party: Janssen Sciences Ireland UC  
ClinicalTrials.gov Identifier: NCT03847376   History of Changes  
Other Study ID Numbers: CR108331  
  TMC278LAHTX2001  
Study First Received: February 18, 2019  
Last Updated: January 6, 2020  

Keywords provided by Janssen Sciences Ireland UC:

Rilpivirine
Long Acting Rilpivirine Injection
HIV
Rilpivirine Expanded Access
Rilpivirine Single Patient Request

Additional relevant MeSH terms:
Rilpivirine

ClinicalTrials.gov processed this data on May 24, 2020
This information is provided by ClinicalTrials.gov.